New advances on critical implications of tumorand metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence

Histology and Histopathology

Volumn 25, Issue 8, 2010, Pages 1057-1073

  Mimeault, M ^a,b   Batra, S K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer stem progenitor cells; Cancer therapies; Epithelial mesenchymal transition; Invasion; Metastases; Molecular therapeutic targets; Solid tumors; Treatment resistance

Indexed keywords

ERINACEIDAE;

BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; CELL; CELL DIFFERENTIATION; CELL TRANSFORMATION; DISEASE COURSE; HUMAN; NEOPLASM; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PATHOLOGY; RECURRENT DISEASE; REVIEW; SIGNAL TRANSDUCTION; STEM CELL;

ADULT; BETA CATENIN; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS; DISEASE PROGRESSION; HUMANS; NEOPLASMS; NEOPLASTIC PROCESSES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECURRENCE; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 77950819301     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (192)

1. -/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 11, 1154-1159.
2. Agelopoulos K., Buerger H. and Brandt B. (2008). Allelic imbalances of the egfr gene as key events in breast cancer progression-the concept of committed progenitor cells. Curr. Cancer Drug Targets. 8, 431-445.
3. Aktas B., Tewes M., Fehm T., Hauch S., Kimmig R. and Kasimir-Bauer S. (2009). Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. 11, R46.
4. Al-Hajj M. and Clarke M. F. (2004). Self-renewal and solid tumor stem cells. Oncogene 23, 7274-7282.
5. Anderson W. F. and Matsuno R. (2006). Breast cancer heterogeneity: a mixture of at least two main types? J. Natl. Cancer Inst. 98, 948-951.
6. Arai F. and Suda T. (2007). Maintenance of quiescent hematopoietic stem cells in the osteoblastic niche. Ann. N. Y. Acad. Sci. 1106, 41-53.
7. Asselin-Labat M. L., Shackleton M., Stingl J., Vaillant F., Forrest N. C., Eaves C. J., Visvader J. E. and Lindeman G. J. (2006). Steroid hormone receptor status of mouse mammary stem cells. J. Natl. Cancer Inst. 98, 1011-1014.
8. Aubert G. and Lansdorp P. M. (2008). Telomeres and aging. Physiol. Rev. 88, 557-579.
9. Bailey J. M., Singh P. K. and Hollingsworth M. A. (2007). Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J. Cell Biochem. 102, 829-839.
10. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., Datar R. H. and Cote R. J. (2006). Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 12, 5615-5621.
11. Bao S., Wu Q., McLendon R. E., Hao Y., Shi Q., Hjelmeland A. B., Dewhirst M. W., Bigner D. D. and Rich J. N. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756-760.
12. Bapat S. A., Mali A. M., Koppikar C. B. and Kurrey N. K. (2005). Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res. 65, 3025-3029.
13. Barker N., Ridgway R. A., van Es J. H., van de Wetering M., Begthel H., van den Born M., Danenberg E., Clarke A. R., Sansom O. J. and Clevers H. (2009). Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608-611.
14. Bauer K. R., Brown M., Cress R. D., Parise C. A. and Caggiano V. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a populationbased study from the California cancer Registry. Cancer 109, 1721-1728.
15. Ben-Porath I., Thomson M. W., Carey V. J., Ge R., Bell G. W., Regev A. and Weinberg R. A. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507.
16. Brabletz T., Jung A., Spaderna S., Hlubek F. and Kirchner T. (2005a). Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 5, 744-749.
17. Brabletz T., Hlubek F., Spaderna S., Schmalhofer O., Hiendlmeyer E., Jung A. and Kirchner T. (2005b). Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymalepithelial transition, stem cells and beta-catenin. Cells Tissues Organs 179, 56-65.
18. Bryder D., Rossi D. J. and Weissman I. L. (2006). Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am. J. Pathol. 169, 338-346.
19. Buyse M., Loi S., van't Veer L., Viale G., Delorenzi M., Glas A. M., d'Assignies M. S., Bergh J., Lidereau R., Ellis P., Harris A., Bogaerts J., Therasse P., Floore A., Amakrane M., Piette F., Rutgers E., Sotiriou C., Cardoso F. and Piccart M. J. (2006). Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 98, 1183-1192.
20. Calza S., Hall P., Auer G., Bjohle J., Klaar S., Kronenwett U., Liu E. T., Miller L., Ploner A., Smeds J., Bergh J. and Pawitan Y. (2006). Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Breast Cancer Res. 8, R34.
21. Carey L. A., Perou C. M., Livasy C. A., Dressler L. G., Cowan D., Conway K., Karaca G., Troester M. A., Tse C. K., Edmiston S., Deming S. L., Geradts J., Cheang M. C., Nielsen T. O., Moorman P. G., Earp H. S. and Millikan R. C. (2006a). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502.
22. Carey L. A., Perou C. M., Livasy C. A., Dressler L. G., Cowan D., Conway K., Karaca G., Troester M. A., Tse C. K., Edmiston S., Deming S. L., Geradts J., Cheang M. C., Nielsen T. O., Moorman P. G., Earp H. S. and Millikan R. C. (2006b). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295, 2492-2502.
23. Catassi A., Servent D., Paleari L., Cesario A. and Russo P. (2008). Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat. Res. 659, 221-231.
24. Cheang M. C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S. K., Perou C. M. and Nielsen T. O. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triplenegative phenotype. Clin. Cancer Res. 14, 1368-1376.
25. Chen Y. C., Hsu H. S., Chen Y. W., Tsai T. H., How C. K., Wang C. Y., Hung S. C., Chang Y. L., Tsai M. L., Lee Y. Y., Ku H. H. and Chiou S. H. (2008). Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE. 3, e2637.
26. Chen Y. C., Chen Y. W., Hsu H. S., Tseng L. M., Huang P. I., Lu K. H., Chen D. T., Tai L. K., Yung M. C., Chang S. C., Ku H. H., Chiou S. H. and Lo W. L. (2009). Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem. Biophys. Res. Commun. 385, 307-313.
27. Chiba T., Miyagi S., Saraya A., Aoki R., Seki A., Morita Y., Yonemitsu Y., Yokosuka O., Taniguchi H., Nakauchi H. and Iwama A. (2008). The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 68, 7742-7749.
28. Clarke R. B., Spence K., Anderson E., Howell A., Okano H. and Potten C. S. (2005). A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev. Biol. 277, 443-456.
29. Clezardin P. and Teti A. (2007). Bone metastasis: pathogenesis and therapeutic implications. Clin. Exp. Metastasis 24, 599-608.
30. Dalerba P., Cho R. W., and Clarke M. F. (2007). Cancer stem cells: models and concepts. Annu. Rev. Med. 58, 267-284. (Pubitemid 46706514)
31. Das B., Tsuchida R., Malkin D., Koren G., Baruchel S. and Yeger H. (2008). Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells 26, 1818-1830.
32. Dawson S. J., Provenzano E. and Caldas C. (2009). Triple negative breast cancers: clinical and prognostic implications. Eur. J. Cancer 45, 27-40.
33. DiMeo T. A., Anderson K., Phadke P., Fan C., Perou C. M., Naber S. and Kuperwasser C. (2009). A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res. 69, 5364-5373.
34. Dontu G., El-Ashry D. and Wicha M. S. (2004). Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol. Metab. 15, 193-197. (Pubitemid 38833988)
35. Dumont N., Wilson M. B., Crawford Y. G., Reynolds P. A., Sigaroudinia M. and Tlsty T. D. (2008). Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc. Natl. Acad. Sci. USA 105, 14867-14872.
36. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., Conticello C., Ruco L., Peschle C. and De Maria R. (2008). Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death. Differ. 15, 504-514.
37. Fang D., Nguyen T. K., Leishear K., Finko R., Kulp A. N., Hotz S., Van Belle P. A., Xu X., Elder D. E. and Herlyn M. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328-9337.
38. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., Karikari C., Alvarez H., Iacobuzio-Donahue C., Jimeno A., Gabrielson K. L., Matsui W., and Maitra A. (2007). Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187-2196.
39. Fillmore C. M. and Kuperwasser C. (2008). Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10, R25.
40. Fodde R. and Brabletz T. (2007). Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 19, 150-158.
41. Friedman S. L. (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology 134, 1655-1669.
42. Friel A. M., Sergent P. A., Patnaude C., Szotek P. P., Oliva E., Scadden D. T., Seiden M. V., Foster R. and Rueda B. R. (2008). Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle 7, 242-249.
43. Fujita N., Jaye D. L., Kajita M., Geigerman C., Moreno C. S., and Wade P. A. (2003). MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 113, 207-219.
44. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., Fiocco R., Foroni C., Dimeco F. and Vescovi A. (2004). Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011-7021.
45. Geminder H., Sagi-Assif O., Goldberg L., Meshel T., Rechavi G., Witz I. P. and Ben-Baruchn A. (2001). A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J. Immunol. 167, 4747-4757.
46. Gerlee P. and Anderson A. R. (2008). A hybrid cellular automaton model of clonal evolution in cancer: the emergence of the glycolytic phenotype. J. Theor. Biol. 250, 705-722.
47. Gilg A. G., Tye S. L., Tolliver L. B., Wheeler W. G., Visconti R. P., Duncan J. D., Kostova F. V., Bolds L. N., Toole B. P., and Maria B. L. (2008). Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin. Cancer Res. 14, 1804-1813.
48. Ginestier C., Hur M. H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C. G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M. S. and Dontu G. (2007). ALDH1 Is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567.
49. Glinsky G. V. (2008). "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J. Clin. Oncol. 26, 2846-2853.
50. Gray-Schopfer V., Wellbrock C. and Marais R. (2007). Melanoma biology and new targeted therapy. Nature 445, 851-857.
51. Griffero F., Daga A., Marubbi D., Capra M. C., Melotti A., Pattarozzi A., Gatti M., Bajetto A., Porcile C., Barbieri F., Favoni R. E., Lo C. M., Zona G., Spaziante R., Florio T. and Corte G. (2009). Different response of human glioma tumor-initiating cells to EGFR kinase inhibitors. J. Biol. Chem. 284, 7138-7148.
52. Gumucio D. L., Fagoonee S., Qiao X. T., Liebert M., Merchant J. L., Altruda F., Rizzetto M. and Pellicano R. (2008). Tissue stem cells and cancer stem cells: potential implications for gastric cancer. Panminerva Med. 50, 65-71.
53. Haffty B. G., Yang Q., Reiss M., Kearney T., Higgins S. A., Weidhaas J., Harris L., Hait W. and Toppmeyer D. (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 24, 5652-5657.
54. Haraguchi N., Utsunomiya T., Inoue H., Tanaka F., Mimori K., Barnard G. F. and Mori M. (2006). Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24, 506-513.
55. Hartmann T. N., Burger J. A., Glodek A., Fujii N. and Burger M. (2005). CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 24, 4462-4471.
56. Hennessy B. T., Gonzalez-Angulo A. M., Stemke-Hale K., Gilcrease M. Z., Krishnamurthy S., Lee J. S., Fridlyand J., Sahin A., Agarwal R., Joy C., Liu W., Stivers D., Baggerly K., Carey M., Lluch A., Monteagudo C., He X., Weigman V., Fan C., Palazzo J., Hortobagyi G. N., Nolden L. K., Wang N. J., Valero V., Gray J. W., Perou C. M. and Mills G. B. (2009). Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 69, 4116-4124.
57. Hermann P. C., Huber S. L., Herrler T., Aicher A., Ellwart J. W., Guba M., Bruns C. J. and Heeschen C. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323.
58. Hope K. J., Jin L. and Dick J. E. (2004). Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 5, 738-743.
59. Horak C. E., Lee J. H., Marshall J. C., Shreeve S. M. and Steeg P. S. (2008). The role of metastasis suppressor genes in metastatic dormancy. APMIS 116, 586-601.
60. Huang D., Gao Q., Guo L., Zhang C., Wei J., Li H., Jing W. J., Han X., Shi Y. and Shih H. L. (2009). Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev. 18, 465-473.
61. Huang Q., Zhang Q. B., Dong J., Wu Y. Y., Shen Y. T., Zhao Y. D., Zhu Y. D., Diao Y., Wang A. D. and Lan Q. (2008). Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer 8, 304.
62. Huntly B. J., Shigematsu H., Deguchi K., Lee B. H., Mizuno S., Duclos N., Rowan R., Amaral S., Curley D., Williams I. R., Akashi K. and Gilliland D. G. (2004). MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587-596.
63. ix-Panabieres C., Riethdorf S. and Pantel K. (2008). Circulating tumor cells and bone marrow micrometastasis. Clin. Cancer Res. 14, 5013-5021.
64. Jamieson C. H., Ailles L. E., Dylla S. J., Muijtjens M., Jones C., Zehnder J. L., Gotlib J., Li K., Manz M. G., Keating A., Sawyers C. L. and Weissman I. L. (2004). Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N. Engl. J. Med. 351, 657-667.
65. Jaspers J. E., Rottenberg S. and Jonkers J. (2009). Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochim. Biophys. Acta 1796, 266-280.
66. Johannessen T. C., Bjerkvig R. and Tysnes B. B. (2008). DNA repair and cancer stem-like cells - Potential partners in glioma drug resistance? Cancer Treat. Rev. 34, 558-567.
67. Kalluri R. and Zeisberg M. (2006). Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401.
68. Katoh M. (2007). Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev. 3, 30-38.
69. Kelly P. N., Dakic A., Adams J. M., Nutt S. L. and Strasserm A. (2007). Tumor growth need not be driven by rare cancer stem cells. Science 317, 337.
70. Kennedy J. A., Barabe F., Poeppl A. G., Wang J. C. and Dick J. E. (2007). Comment on "Tumor growth need not be driven by rare cancer stem cells". Science 318, 1722.
71. Kim C. F., Jackson E. L., Woolfenden A. E., Lawrence S., Babar I., Vogel S., Crowley D., Bronson R. T. and Jacks T. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823-835.
72. Kirkland S. C. (2009). Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells. Br. J. Cancer 101, 320-326.
73. Kleeff J., Beckhove P., Esposito I., Herzig S., Huber P. E., Lohr J. M. and Friess H. (2007). Pancreatic cancer microenvironment. Int. J. Cancer 121, 699-705.
74. Kondoh H. (2008). Cellular life span and the Warburg effect. Exp. Cell Res. 314, 1923-1928.
75. Kong D., Wang Z., Sarkar S. H., Li Y., Banerjee S., Saliganan A., Kim H. R., Cher M. L. and Sarkar F. H. (2008). Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 26, 1425-1435.
76. Kurrey N. K., Jalgaonkar S. P., Joglekar A. V., Ghanate A. D., Chaskar P. D., Doiphode R. Y. and Bapat S. A. (2009). Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27, 2059-2068.
77. Laakso M., Tanner M., Nilsson J., Wiklund T., Erikstein B., Kellokumpu-Lehtinen P., Malmstrom P., Wilking N., Bergh J. and Isola J. (2006). Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin. Cancer Res. 12, 4185-4191.
78. Lacroix M. (2006). Significance, detection and markers of disseminated breast cancer cells. Endocr. Relat. Cancer 13, 1033-1067.
79. Langley R. R. and Fidler I. J. (2007). Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 28, 297-321.
80. Le Tourneau C., Faivre S. and Raymond E. (2008). New developments in multitargeted therapy for patients with solid tumours. Cancer Treat. Rev. 34, 37-48.
81. Levina V., Marrangoni A. M., DeMarco R., Gorelik E. and Lokshin A. E. (2008). Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE. 3, e3077.
82. Li L. and Neaves W. B. (2006). Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 66, 4553-4557.
83. Li X., Lewis M. T., Huang J., Gutierrez C., Osborne C. K., Wu M. F., Hilsenbeck S. G., Pavlick A., Zhang X., Chamness G. C., Wong H., Rosen J. and Chang J. C. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100, 672-679.
84. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I. R., Lu L., Irvin D., Black K. L. and Yu J. S. (2006a). Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5, 67.
85. Liu R., Wang X., Chen G. Y., Dalerba P., Gurney A., Hoey T., Sherlock G., Lewicki J., Shedden K. and Clarke M. F. (2007). The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217-226.
86. Liu S., Dontu G., Mantle I. D., Patel S., Ahn N. S., Jackson K. W., Surim P. and Wicha M. S. (2006b). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063-6071.
87. Loebinger M. R., Giangreco A., Groot K. R., Prichard L., Allen K., Simpson C., Bazley L., Navani N., Tibrewal S., Davies D. and Janes S. M. (2008). Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br. J. Cancer 98, 380-387.
88. Ma S., Lee T. K., Zheng B. J., Chan K. W. and Guan X. Y. (2008). CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27, 1749-1758.
89. MacDonald T. J., Rood B. R., Santi M. R., Vezina G., Bingaman K., Cogen P. H. and Packer R. J. (2003). Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist 8, 174-186.
90. Maitland N. J., Bryce S. D., Stower M. J. and Collins A. T. (2006). Prostate cancer stem cells: a target for new therapies. Ernst. Schering. Found. Symp. Proc. 5, 155-179.
91. Mani S. A., Guo W., Liao M. J., Eaton E. N., Ayyanan A., Zhou A. Y., Brooks M., Reinhard F., Zhang C. C., Shipitsin M., Campbell L. L., Polyak K., Brisken C., Yang J. and Weinbergm R. A. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
92. Mannelli M., Simi L., Gagliano M. S., Opocher G., Ercolino T., Becherini L. and Parenti G. (2007). Genetics and biology of pheochromocytoma. Exp. Clin. Endocrinol. Diabetes 115, 160-165.
93. Marusyk A. and DeGregori J. (2008). Declining cellular fitness with age promotes cancer initiation by selecting for adaptive oncogenic mutations. Biochim. Biophys. Acta 1785, 1-11.
94. Matsui W., Huff C. A., Wang Q., Malehorn M. T., Barber J., Tanhehco Y., Smith B. D., Civin C. I. and Jones R. J. (2004). Characterization of clonogenic multiple myeloma cells. Blood 103, 2332-2336.
95. Matsui W., Wang Q., Barber J. P., Brennan S., Smith B. D., Borrello I., McNiece I., Lin L., Ambinder R. F., Peacock C., Watkins D. N., Huff C. A. and Jones R. J. (2008). Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res. 68, 190-197.
96. Mimeault M. and Batra S. K. (2006). Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells 24, 2319-2345.
97. Mimeault M. and Batra S. K. (2007a). Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications. Cancer Metastasis Rev. 26, 203-214.
98. Mimeault M. and Batra S. K. (2007b). Interplay of distinct growth factors during epithelial-mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann. Oncol. 18, 1605-1619.
99. Mimeault M. and Batra S. K. (2008a). Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev. 4, 27-49.
100. Mimeault M. and Batra S. K. (2008b). Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer. Gut 57, 1456-1468.
101. Mimeault M. and Batra S. K. (2008c). Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med. 50, 3-18.
102. Mimeault M. and Batra S. K. (2008d). Recent advances on the development of novel anti-cancer drugs targeting cancer stem/progenitor cells. Drug Develop. Res. 69, 415-430.
103. Mimeault M. and Batra S. K. (2009). Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res. Rev. 8, 94-112.
104. Mimeault M., Hauke R. and Batra S. K. (2007a). Stem cells - A revolution in therapeutics-Recent advances on the stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin. Pharmacol. Ther. 82, 252-264.
105. Mimeault M., Hauke R., Mehta P. P. and Batra S. K. (2007b). Recent advances on cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Mol. Cell. Med. 11, 981-1011.
106. Mimeault M., Hauke R. and Batra S. K. (2008a). Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin. Pharmacol. Ther 83, 673-691.
107. Mimeault M., Mehta P. P., Hauke R. and Batra S. K. (2008b). Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr. Rev. 29, 234-252.
108. Misra S., Toole B. P. and Ghatak S. (2006). Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J. Biol. Chem. 281, 34936-34941.
109. Morel A. P., Lievre M., Thomas C., Hinkal G., Ansieau S. and Puisieux A. (2008). Generation of breast cancer stem cells through epithelialmesenchymal transition. PLoS ONE 3, e2888.
110. Moustakas A. and Heldin C. H. (2007). Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 98, 1512-1520.
111. Moustakas A. and Heldin C. H. (2008). Dynamic control of TGF-beta signaling and its links to the cytoskeleton. FEBS Lett. 582, 2051-2065.
112. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M. E., McClanahan T., Murphy E., Yuan W., Wagner S. N., Barrera J. L., Mohar A., Verastegui E. and Zlotnik A. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410, 50-56.
113. Nakagawara A. and Ohira M. (2004). Comprehensive genomics linking between neural development and cancer: neuroblastoma as a model. Cancer Lett. 204, 213-224.
114. Nicolis S. K. (2007). Cancer stem cells and "stemness" genes in neurooncology. Neurobiol. Dis. 25, 217-229.
115. Nielsen T. O., Hsu F. D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., Akslen L. A., Ragaz J., Gown A. M., Gilks C. B., van de Rijn M., and Perou C. M. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10, 5367-5374.
116. Nijhof J. G., van Pelt C., Mulder A. A., Mitchell D. L., Mullenders L. H., and de Gruijl F. R. (2007). Epidermal stem and progenitor cells in murine epidermis accumulate UV damage despite NER proficiency. Carcinogenesis 28, 792-800.
117. Olivotto M. and Dello S. P. (2008). Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells. Cell Cycle 7, 176-187.
118. Onoue T., Uchida D., Begum N. M., Tomizuka Y., Yoshida H. and Sato M. (2006). Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int. J. Oncol. 29, 1133-1138.
119. Park D. M., Zhuang Z., Chen L., Szerlip N., Maric I., Li J., Sohn T., Kim S. H., Lubensky I. A., Vortmeyer A. O., Rodgers G. P., Oldfield E. H. and Lonser R. R. (2007). von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells. PLoS Med. 4, e60.
120. Patrawala L., Calhoun T., Schneider-Broussard R., Li H., Bhatia B., Tang S., Reilly J. G., Chandra D., Zhou J., Claypool K., Coghlan L. and Tang D. G. (2006). Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25, 1696-1708.
121. Patrawala L., Calhoun-Davis T., Schneider-Broussard R., and Tang D. G. (2007). Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+{alpha}2{beta}1+ cell population is enriched in tumor-initiating cells. Cancer Res. 67, 6796-6805.
122. Phillips T. M., McBride W. H. and Pajonk F. (2006). The response of CD24 (-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 98, 1777-1785.
123. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M. A. and Daidone M. G. (2005). Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65, 5506-5511.
124. Prince M. E., Sivanandan R., Kaczorowski A., Wolf G. T., Kaplan M. J., Dalerba P., Weissman I. L., Clarke M. F. and Ailles L. E. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 104, 973-978.
125. Quintana E., Shackleton M., Sabel M. S., Fullen D. R., Johnson T. M. and Morrison S. J. (2008). Efficient tumour formation by single human melanoma cells. Nature 456, 593-598.
126. Rak J., Milsom C., and Yu J. (2008). Vascular determinants of cancer stem cell dormancy-do age and coagulation system play a role? APMIS 116, 660-676.
127. Rakha E. A., El-Sayed M. E., Green A. R., Lee A. H., Robertson J. F. and Ellis I. O. (2007). Prognostic markers in triple-negative breast cancer. Cancer 109, 25-32.
128. Ratajczak M. Z., Kucia M., Reca R., Majka M., Janowska-Wieczorek A. and Ratajczak J. (2004). Stem cell plasticity revisited: CXCR4-positive cells expressing mRNA for early muscle, liver and neural cells 'hide out' in the bone marrow. Leukemia 18, 29-40.
129. Ratajczak M. Z., Zuba-Surma E., Kucia M., Reca R., Wojakowski W. and Ratajczak J. (2006). The pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20, 1915-1924.
130. Reis-Filho J. S. and Tutt A. N. (2008). Triple negative tumours: a critical review. Histopathology 52, 108-118.
131. Ricci-Vitiani L., Lombardi D. G., Pilozzi E., Biffoni M., Todaro M., Peschle C. and De Maria R. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115.
132. Rich J. N. (2007). Cancer stem cells in radiation resistance. Cancer Res. 67, 8980-8984.
133. Riethdorf S., Wikman H. and Pantel K. (2008). Review: Biological relevance of disseminated tumor cells in cancer patients. Int. J. Cancer 123, 1991-2006.
134. Rizo A., Vellenga E., de Haan G. and Schuringa J. J. (2006). Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum. Mol. Genet. 15, R210-R219.
135. Ross R. A. and Spengler B. A. (2007). Human neuroblastoma stem cells. Semin. Cancer Biol. 17, 241-247.
136. Salmaggi A., Boiardi A., Gelati M., Russo A., Calatozzolo C., Ciusani E., Sciacca F. L., Ottolina A., Parati E. A., La Porta C., Alessandri G., Marras C., Croci D. and De Rossi M. (2006). Glioblastoma-derived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia 54, 850-860.
137. Sarkar F. H., Li Y., Wang Z. and Kong D. (2008). NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int. Rev. Immunol. 27, 293-319.
138. Sathornsumetee S., Rich J. N., and Reardon D. A. (2007). Diagnosis and treatment of high-grade astrocytoma. Neurol. Clin. 25, 1111-39.
139. Sato M., Shames D. S., Gazdar A. F. and Minna J. D. (2007). A translational view of the molecular pathogenesis of lung cancer. J. Thorac. Oncol. 2, 327-343.
140. Schatton T., Murphy G. F., Frank N. Y., Yamaura K., Waaga-Gasser A. M., Gasser M., Zhan Q., Jordan S., Duncan L. M., Weishaupt C., Fuhlbrigge R. C., Kupper T. S., Sayegh M. H. and Frank M. H. (2008). Identification of cells initiating human melanomas. Nature 451, 345-349.
141. Schneider B. P., Winer E. P., Foulkes W. D., Garber J., Perou C. M., Richardson A., Sledge G. W. and Carey L. A. (2008). Triple-negative breast cancer: risk factors to potential targets. Clin. Cancer Res. 14, 8010-8018.
142. Sengupta A., Banerjee D., Chandra S., Banerji S. K., Ghosh R., Roy R. and Banerjee S. (2007). Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 21, 949-955.
143. Shah A. N., Summy J. M., Zhang J., Park S. I., Parikh N. U. and Gallick G. E. (2007). Development and characterization of gemcitabineresistant pancreatic tumor cells. Ann. Surg. Oncol. 14, 3629-3637.
144. Sharpless N. E. and DePinho R. A. (2007). How stem cells age and why this makes us grow old. Nat. Rev. Mol. Cell Biol. 8, 703-713.
145. She J. J., Zhang P. G., Wang Z. M., Gan W. M. and Che X. M. (2008). Identification of side population cells from bladder cancer cells by dyecycle violet staining. Cancer Biol. Ther 7, 1663-1668.
146. Shi G. M., Xu Y., Fan J., Zhou J., Yang X. R., Qiu S. J., Liao Y., Wu W. Z., Ji Y., Ke A. W., Ding Z. B., He Y. Z., Wu B., Yang G. H., Qin W. Z., Zhang W., Zhu J., Min Z. H. and Wu Z. Q. (2008). Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J. Cancer Res. Clin. Oncol. 134, 1155-1163.
147. Shipitsin M., Campbell L. L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., Nikolskaya T., Serebryiskaya T., Beroukhim R., Hu M., Halushka M. K., Sukumar S., Parker L. M., Anderson K. S., Harris L. N., Garber J. E., Richardson A. L., Schnitt S. J., Nikolsky Y., Gelman R. S. and Polyak K. (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273.
148. Shiras A., Chettiar S. T., Shepal V., Rajendran G., Prasad G. R. and Shastry P. (2007). Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma. Stem Cells 25, 1478-1489.
149. Shmelkov S. V., Butler J. M., Hooper A. T., Hormigo A., Kushner J., Milde T., St Clair R., Baljevic M., White I., Jin D. K., Chadburn A., Murphy A. J., Valenzuela D. M., Gale N. W., Thurston G., Yancopoulos G. D., D'Angelica M., Kemeny N., Lyden D. and Rafii S. (2008). CD133 expression is not restricted to stem cells, and both CD133+ and CD133-metastatic colon cancer cells initiate tumors. J. Clin. Invest. 118, 2111-2120.
150. Singh S. K., Hawkins C., Clarke I. D., Squire J. A., Bayani J., Hide T., Henkelman R. M., Cusimano M. D. and Dirks P. B. (2004). Identification of human brain tumour initiating cells. Nature 432, 396-401.
151. Sorlie T., Wang Y., Xiao C., Johnsen H., Naume B., Samaha R. R. and Borresen-Dale A. L. (2006). Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 7, 127.
152. Sorscher S. M. (2007). Biological therapy update in colorectal cancer. Expert Opin. Biol. Ther. 7, 509-519.
153. Spaderna S., Schmalhofer O., Hlubek F., Jung A., Kirchner T. and Brabletz T. (2007). Epithelial-mesenchymal and mesenchymalepithelial transitions during cancer progression. Verh. Dtsch. Ges. Pathol. 91, 21-28.
154. Steeg P. S. and Theodorescu D. (2008). Metastasis: a therapeutic target for cancer. Nat. Clin. Pract. Oncol. 5, 206-219.
155. Storci G., Sansone P., Trere D., Tavolari S., Taffurelli M., Ceccarelli C., Guarnieri T., Paterini P., Pariali M., Montanaro L., Santini D., Chieco P. and Bonafe M. (2008). The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J. Pathol. 214, 25-37.
156. Sun Y. X., Fang M., Wang J., Cooper C. R., Pienta K. J. and Taichman R. S. (2007). Expression and activation of alpha (v) beta (3) integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 67, 61-73.
157. SunY. X., Schneider A., Jung Y., Wang J., Dai J., Wang J., Cook K., Osman N. I., Koh-Paige A. J., Shim H., Pienta K. J., Keller E. T., McCauley L. K. and Taichman R. S. (2005). Skeletal localization and neutralization of the SDF-1 (CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J. Bone Miner. Res. 20, 318-329.
158. Sun Y. X., Wang J., Shelburne C. E., Lopatin D. E., Chinnaiyan A. M., Rubin M. A., Pienta K. J. and Taichman R. S. (2003). Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J. Cell Biochem. 89, 462-473.
159. Sung J. M., Cho H. J., Yi H., Lee C. H., Kim H. S., Kim D. K., bd El-Aty A. M., Kim J. S., Landowski C. P., Hediger M. A. and Shin H. C. (2008). Characterization of a stem cell population in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 371, 163-167.
160. Tang P., Wang X., Schiffhauer L., Wang J., Bourne P., Yang Q., Quinn A. and Hajdu S. (2006). Expression patterns of ER-alpha, PR, HER-2/neu, and EGFR in different cell origin subtypes of high grade and non-high grade ductal carcinoma in situ. Ann. Clin. Lab. Sci. 36, 137-143.
161. Tchernev G. and Orfanos C. E. (2007). Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: preliminary findings. J. Cutan. Pathol. 34, 247-256.
162. Teuliere J., Faraldo M. M., Deugnier M. A., Shtutman M., Ben-Ze'ev A., Thiery J. P. and Glukhova M. A. (2005). Targeted activation of betacatenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development 132, 267-277.
163. Thiery J. P. and Sleeman J. P. (2006). Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131-142.
164. Tiffin N., Williams R. D., Shipley J. and Pritchard-Jones K. (2003). PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br. J. Cancer 89, 327-332.
165. Todaro M., Alea M. P., Di Stefano A. B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.-P. and Stassi G. (2007). Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1, 389-402.
166. Toole B. P. and Slomiany M. G. (2008). Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin. Cancer Biol. 18, 244-250.
167. Tostar U., Malm C. J., Meis-Kindblom J. M., Kindblom L. G., Toftgard R. and Unden A. B. (2006). Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J. Pathol. 208, 17-25.
168. Trumpp A. and Wiestler O. D. (2008). Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat. Clin. Pract. Oncol. 5, 337-347.
169. Tso C. L., Shintaku P., Chen J., Liu Q., Liu J., Chen Z., Yoshimoto K., Mischel P. S., Cloughesy T. F., Liau L. M. and Nelson S. F. (2006). Primary glioblastomas express mesenchymal stem-like properties. Mol. Cancer Res. 4, 607-619.
170. Turley E. A., Veiseh M., Radisky D. C. and Bissell M. J. (2008). Mechanisms of disease: epithelial-mesenchymal transition-does cellular plasticity fuel neoplastic progression? Nat. Clin. Pract. Oncol. 5, 280-290.
171. Vaish M. (2007). Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol. Cancer 6, 26.
172. Vincent-Salomon A., Bidard F. C. and Pierga J. Y. (2008). Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. J. Clin. Pathol. 61, 570-576.
173. Walton J. D., Kattan D. R., Thomas S. K., Spengler B. A., Guo H. F., Biedler J. L., Cheung N. K. and Ross R. A. (2004). Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 6, 838-845.
174. Wang J., Guo L. P., Chen L. Z., Zeng Y. X. and Lu S. H. (2007a). Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 67, 3716-3724.
175. Wang X., Belguise K., Kersual N., Kirsch K. H., Mineva N. D., Galtier F., Chalbos D. and Sonenshein G. E. (2007b). Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol. 9, 470-478.
176. Wang Z., Jiang C. and Lu J. (2002). Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol. Carcinog. 34, 113-120.
177. Wei C., Guomin W., Yujun L. and Ruizhe Q. (2007). Cancer stem-like cells in human prostate carcinoma cells DU145: The seeds of the cell line? Cancer Biol. Ther. 6, 763-768.
178. Widera D., Kaus A., Kaltschmidt C. and Kaltschmidt B. (2008). Neural stem cells, inflammation and NF-kappaB: basic principle of maintenance and repair or origin of brain tumours? J. Cell Mol. Med. 12, 459-470.
179. Wilson A. and Trumpp A. (2006). Bone-marrow haematopoietic-stemcell niches. Nat. Rev. Immunol. 6, 93-106.
180. Wright M. H., Calcagno A. M., Salcido C. D., Carlson M. D., Ambudkar S. V. and Varticovski L. (2008). Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 10, R10.
181. Yang Z. F., Ho D. W., Ng M. N., Lau C. K., Yu W. C., Ngai P., Chu P. W., Lam C. T., Poon R. T. and Fan S. T. (2008a). Significance of CD90 (+) cancer stem cells in human liver cancer. Cancer Cell 13, 153-166. (Pubitemid 351163165)
182. Yang Z. F., Ngai P., Ho D. W., Yu W. C., Ng M. N., Lau C. K., Li M. L., Tam K. H., Lam C. T., Poon R. T. and Fan S. T. (2008b). Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47, 919-928. (Pubitemid 351449683)
183. Young N. S., Scheinberg P. and Calado R. T. (2008). Aplastic anemia. Curr. Opin. Hematol. 15, 162-168.
184. Yu S. C., Ping Y. F., Yi L., Zhou Z. H., Chen J. H., Yao X. H., Gao L., Wang J. M. and Bian X. W. (2008). Isolation and characterization of cancer stem cells from a human glioblastoma cell line U87. Cancer Lett. 265, 124-134.
185. Yuan X., Curtin J., Xiong Y., Liu G., Waschsmann-Hogiu S., Farkas D. L., Black K. L. and Yu J. S. (2004). Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 23, 9392-9400.
186. Zhang S., Balch C., Chan M. W., Lai H. C., Matei D., Schilder J. M., Yan P. S., Huang T. H. and Nephew K. P. (2008a). Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311-4320.
187. Zhang X., Komaki R., Wang L., Fang B. and Chang J. Y. (2008b). Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin. Cancer Res. 14, 2813-2823.
188. Zhao C., Deng W. and Gage F. H. (2008). Mechanisms and functional implications of adult neurogenesis. Cell 132, 645-660.
189. Zhong X., Li Y., Peng F., Huang B., Lin J., Zhang W., Zheng J., Jiang R., Song G. and Ge J. (2007). Identification of tumorigenic retinal stem-like cells in human solid retinoblastomas. Int. J. Cancer 121, 2125-2131.
190. Zhou B. P. and Hung M. C. (2005). Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle 4, 772-776.
191. Zhou Z., Flesken-Nikitin A. and Nikitin A. Y. (2007). Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res. 67, 5683-5690.
192. Zhu L., Gibson P., Currle D. S., Tong Y., Richardson R. J., Bayazitov I. T., Poppleton H., Zakharenko S., Ellison D. W. and Gilbertson R. J. (2009). Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 457, 603-607.